| Literature DB >> 16298527 |
Amos B Smith1, Adam K Charnley, Hironori Harada, Jason J Beiger, Louis-David Cantin, Craig S Kenesky, Ralph Hirschmann, Sanjeev Munshi, David B Olsen, Mark W Stahlhut, William A Schleif, Lawrence C Kuo.
Abstract
A series of monopyrrolinone-based HIV-1 protease inhibitors possessing rationally designed P2' side chains have been synthesized and evaluated for activity against wild-type HIV-1 protease. The most potent inhibitor displays subnanomolar potency in vitro for the wild-type HIV-1 protease. Additionally, the monopyrrolinone inhibitors retain potency in cellular assays against clinically significant mutant forms of the virus. X-ray structures of these inhibitors bound in the wild-type enzyme reveal important insights into the observed biological activity.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16298527 DOI: 10.1016/j.bmcl.2005.11.011
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823